STOCK TITAN
  1. Home
  2. Sec-filings
  3. FENC
  4. [Form 4] FENNEC PHARMACEUTICALS INC. Insider Trading Activity

Fennec Pharma CFO gets 1,703-share stock grant

FENNEC PHARMACEUTICALS INC.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. (FENC) reported an insider equity transaction by Chief Financial Officer Robert Andrade. On 2026-08-31, Andrade acquired 1,703 common shares at a reported price of $0.00 per share, characterized as a grant or award. A footnote states these shares represent releases from restrictions on shares originally awarded on 2024-05-16 and 2025-03-28. Following this release, Andrade directly holds 241,306 common shares.

Positive

  • None.

Negative

  • None.
Insider Andrade Robert
Role CHIEF FINANCIAL OFFICER
Type Security Shares Price Value
Grant/Award Common shares F1 1,703 $0.00 $0.00
Holdings After Transaction: Common shares — 241,306 shares (Direct)
Footnotes (1)
  1. F1. Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025.
Shares acquired 1,703 common shares Grant, award, or other acquisition on 2026-08-31
Transaction price per share $0.00 per share Reported for the 1,703-share award transaction
Shares owned after transaction 241,306 common shares Direct holdings of Robert Andrade following the 2026-08-31 transaction
Award dates for underlying shares 2024-05-16 and 2025-03-28 Original award dates for shares whose restrictions were released
Number of acquire-type transactions 1 transaction Transaction summary acquireCount
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
Common shares financial
"security_title: "Common shares""
Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.
released from restriction financial
"Represents shares released from restriction from shares awarded"

FAQ

What insider transaction did FENC report for Robert Andrade on this Form 4?
FENNEC PHARMACEUTICALS INC. reported that CFO Robert Andrade acquired 1,703 common shares on 2026-08-31 through a grant, award, or other acquisition, with a reported price of $0.00 per share and direct ownership.

How many FENC shares does Robert Andrade hold after this transaction?
After the reported transaction, Chief Financial Officer Robert Andrade directly holds 241,306 common shares of FENNEC PHARMACEUTICALS INC., as stated in the Form 4 filing’s post-transaction holdings field.

What is the nature of the 1,703 FENC shares reported in this Form 4?
The 1,703 common shares reported represent shares released from restriction from shares previously awarded on 2024-05-16 and 2025-03-28, according to the transaction footnote in the filing.

Was the FENC insider transaction a market purchase or sale?
No market purchase or sale is reported. The Form 4 identifies the code as A, described as a grant, award, or other acquisition, with a $0.00 per-share price, indicating a compensation-related equity event rather than an open-market trade.

Is there any indication of a Rule 10b5-1 trading plan in this FENC Form 4?
The Form 4 indicates the Rule 10b5-1 checkbox is not affirmed (aff_10b5_one is false), and the footnote describes only the release of restrictions on prior awards, with no reference to a trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Andrade Robert
(Last)(First)(Middle)
C/O FENNEC PHARMACEUTICALS, INC.
PO BOX 13628, 68 TW ALEXANDER DRIVE
(Street)
RESEARCH TRIANGLE PARK NORTH CAROLINA 27709
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF FINANCIAL OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common shares(1)08/31/2026A1,703A$0241,306D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025.
/s/ Robert Andrade08/31/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR